Company: PFSA
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112723
Chunk: 9

Company: Profusa, Inc.
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
’s first offering in the European Union, the Lumee™ Oxygen Platform, is designed to report reliable
tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee™ Oxygen Platform has been designed for
use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing
of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly;
and reconstructive surgery.

The Company’s research and development efforts are primarily
focused on its Lumee™ Glucose Platform which is a system designed to monitor glucose levels in interstitial fluid, continuously
and long-term. A tiny, biocompatible gel injected under the skin acts as a continuous glucose monitor (“CGM”) for several
months. The ability of Lumee™ Glucose to provide continuous glucose monitoring with only an initial single injection, is an attractive
alternative for people with diabetes to manage their disease without the need for frequent finger sticks required by standard glucometers,
or the need for weekly sensor replacement as required by current short-term needle-type CGMs.

On July 11, 2025 (the “Closing Date”), NorthView Acquisition
Corporation (“Northview”), consummated its previously announced business combination (the “Business Combination”)
with Profusa, Inc., a California corporation (“Legacy Profusa”), pursuant to that certain Merger Agreement and Plan of Reorganization,
dated as of November 7, 2022 (as the same has been amended, supplemented or otherwise modified from time to time, the “Merger Agreement”),
between Northview, Legacy Profusa, and NV Profusa Merger Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Northview
(“Merger Sub” and, collectively, the “Parties”). The consummation of the Business Combination involved the merger
(the “Merger”) of Merger Sub with and into Legacy Profusa, pursuant to which, at the closing of the transactions contemplated
by the Merger Agreement (the “Closing”), the separate corporate existence of Merger Sub ceased, with Legacy Profusa as the
surviving corporation becoming a wholly-owned subsidiary of Northview, pursuant to the terms of the Merger Agreement. As a result of the
Business Combination, Northview owns 100% of the outstanding common stock of Legacy Profusa. In connection with the closing of the Business
Combination, Northview changed